Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes

A. Maraveyas, B. Baban, D. Kennard, G. A.W. Rook, M. Westby, J. M. Grange, P. Lydyard, J. L. Stanford, M. Jones, P. Selby, A. G.D. Dalgleish

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Purpose: This phase I-II study was designed to assess safety and clinical efficacy of SRLI72 vaccine in patients with advanced stage IV (AJCC) malignant melanoma. Induction of intracellular cytokines (IL-2 and INF-γ) in peripheral blood lymphocytes (PBLCs) from these patients was assayed and correlated to clinical outcome. Patients and methods: SRL172 was administered intradermally to 24 patients with stage IV malignant melanoma, initially at 15-day intervals for three vaccinations and then at monthly intervals. Lymphocyte activation for cytokines in PBLCs was assayed prior to each vaccine administration using at FACS-based intracellular cytokine assay. Survival was compared to historical controls. Results: The vaccination schedule resulted in sustained intracellular IL-2 induction in PBLCs in 9 of 23 patients (39%) who received at least three doses. Cytokine induction became apparent within the first three administrations of vaccine and was maximal at 8-12 weeks. Induction of intracellular IL-2 production (group 1) was associated with improved survival (P < 0.036). The median survival of the nine patients demonstrating IL-2 induction was 59 (95% confidence interval (95% CI): 47-71) weeks compared to 31 (95% CI: 1844) weeks for the non- inducers. Induction of INF-γ (group 2) was found in 10 patients and 6 patients had IL-2 and INF-γ induction(group 3). There was no survival advantage for these patient groups. Although no objective responses were documented the group as a whole had a median survival of 44 (95c% CI: 31-59) weeks which is better than that of historical controls. SRL 172 was safe and well tolerated. Conclusion: SRL172 is effective in inducing intracellular IL- 2 responses in PBLCs of a significant number of patients with stage IV (AJCC) melanoma. This is correlated with improved survival. The survival analysis is sufficiently encouraging to suggest that further prospective trials are justified. The methodology we present in this study may help in developing surrogate markers that will allow rational immunotherapeutic strategies to be designed for cancer patients.

Original languageEnglish (US)
Pages (from-to)817-824
Number of pages8
JournalAnnals of Oncology
Volume10
Issue number7
DOIs
StatePublished - Aug 15 1999

Fingerprint

Immunotherapy
Interleukin-2
Melanoma
Lymphocytes
Survival
Cytokines
Vaccines
Vaccination
SRL172
Confidence Intervals
Survival Analysis
Lymphocyte Activation
Appointments and Schedules
Biomarkers
Safety

Keywords

  • Cancer vaccines
  • Cytokines
  • Melanoma
  • Mycobacterium vaccae (SRL 172)

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy : Correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. / Maraveyas, A.; Baban, B.; Kennard, D.; Rook, G. A.W.; Westby, M.; Grange, J. M.; Lydyard, P.; Stanford, J. L.; Jones, M.; Selby, P.; Dalgleish, A. G.D.

In: Annals of Oncology, Vol. 10, No. 7, 15.08.1999, p. 817-824.

Research output: Contribution to journalArticle

Maraveyas, A. ; Baban, B. ; Kennard, D. ; Rook, G. A.W. ; Westby, M. ; Grange, J. M. ; Lydyard, P. ; Stanford, J. L. ; Jones, M. ; Selby, P. ; Dalgleish, A. G.D. / Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy : Correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. In: Annals of Oncology. 1999 ; Vol. 10, No. 7. pp. 817-824.
@article{16e059a5a4674c559f9691f03c2ee182,
title = "Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes",
abstract = "Purpose: This phase I-II study was designed to assess safety and clinical efficacy of SRLI72 vaccine in patients with advanced stage IV (AJCC) malignant melanoma. Induction of intracellular cytokines (IL-2 and INF-γ) in peripheral blood lymphocytes (PBLCs) from these patients was assayed and correlated to clinical outcome. Patients and methods: SRL172 was administered intradermally to 24 patients with stage IV malignant melanoma, initially at 15-day intervals for three vaccinations and then at monthly intervals. Lymphocyte activation for cytokines in PBLCs was assayed prior to each vaccine administration using at FACS-based intracellular cytokine assay. Survival was compared to historical controls. Results: The vaccination schedule resulted in sustained intracellular IL-2 induction in PBLCs in 9 of 23 patients (39{\%}) who received at least three doses. Cytokine induction became apparent within the first three administrations of vaccine and was maximal at 8-12 weeks. Induction of intracellular IL-2 production (group 1) was associated with improved survival (P < 0.036). The median survival of the nine patients demonstrating IL-2 induction was 59 (95{\%} confidence interval (95{\%} CI): 47-71) weeks compared to 31 (95{\%} CI: 1844) weeks for the non- inducers. Induction of INF-γ (group 2) was found in 10 patients and 6 patients had IL-2 and INF-γ induction(group 3). There was no survival advantage for these patient groups. Although no objective responses were documented the group as a whole had a median survival of 44 (95c{\%} CI: 31-59) weeks which is better than that of historical controls. SRL 172 was safe and well tolerated. Conclusion: SRL172 is effective in inducing intracellular IL- 2 responses in PBLCs of a significant number of patients with stage IV (AJCC) melanoma. This is correlated with improved survival. The survival analysis is sufficiently encouraging to suggest that further prospective trials are justified. The methodology we present in this study may help in developing surrogate markers that will allow rational immunotherapeutic strategies to be designed for cancer patients.",
keywords = "Cancer vaccines, Cytokines, Melanoma, Mycobacterium vaccae (SRL 172)",
author = "A. Maraveyas and B. Baban and D. Kennard and Rook, {G. A.W.} and M. Westby and Grange, {J. M.} and P. Lydyard and Stanford, {J. L.} and M. Jones and P. Selby and Dalgleish, {A. G.D.}",
year = "1999",
month = "8",
day = "15",
doi = "10.1023/A:1008307821189",
language = "English (US)",
volume = "10",
pages = "817--824",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy

T2 - Correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes

AU - Maraveyas, A.

AU - Baban, B.

AU - Kennard, D.

AU - Rook, G. A.W.

AU - Westby, M.

AU - Grange, J. M.

AU - Lydyard, P.

AU - Stanford, J. L.

AU - Jones, M.

AU - Selby, P.

AU - Dalgleish, A. G.D.

PY - 1999/8/15

Y1 - 1999/8/15

N2 - Purpose: This phase I-II study was designed to assess safety and clinical efficacy of SRLI72 vaccine in patients with advanced stage IV (AJCC) malignant melanoma. Induction of intracellular cytokines (IL-2 and INF-γ) in peripheral blood lymphocytes (PBLCs) from these patients was assayed and correlated to clinical outcome. Patients and methods: SRL172 was administered intradermally to 24 patients with stage IV malignant melanoma, initially at 15-day intervals for three vaccinations and then at monthly intervals. Lymphocyte activation for cytokines in PBLCs was assayed prior to each vaccine administration using at FACS-based intracellular cytokine assay. Survival was compared to historical controls. Results: The vaccination schedule resulted in sustained intracellular IL-2 induction in PBLCs in 9 of 23 patients (39%) who received at least three doses. Cytokine induction became apparent within the first three administrations of vaccine and was maximal at 8-12 weeks. Induction of intracellular IL-2 production (group 1) was associated with improved survival (P < 0.036). The median survival of the nine patients demonstrating IL-2 induction was 59 (95% confidence interval (95% CI): 47-71) weeks compared to 31 (95% CI: 1844) weeks for the non- inducers. Induction of INF-γ (group 2) was found in 10 patients and 6 patients had IL-2 and INF-γ induction(group 3). There was no survival advantage for these patient groups. Although no objective responses were documented the group as a whole had a median survival of 44 (95c% CI: 31-59) weeks which is better than that of historical controls. SRL 172 was safe and well tolerated. Conclusion: SRL172 is effective in inducing intracellular IL- 2 responses in PBLCs of a significant number of patients with stage IV (AJCC) melanoma. This is correlated with improved survival. The survival analysis is sufficiently encouraging to suggest that further prospective trials are justified. The methodology we present in this study may help in developing surrogate markers that will allow rational immunotherapeutic strategies to be designed for cancer patients.

AB - Purpose: This phase I-II study was designed to assess safety and clinical efficacy of SRLI72 vaccine in patients with advanced stage IV (AJCC) malignant melanoma. Induction of intracellular cytokines (IL-2 and INF-γ) in peripheral blood lymphocytes (PBLCs) from these patients was assayed and correlated to clinical outcome. Patients and methods: SRL172 was administered intradermally to 24 patients with stage IV malignant melanoma, initially at 15-day intervals for three vaccinations and then at monthly intervals. Lymphocyte activation for cytokines in PBLCs was assayed prior to each vaccine administration using at FACS-based intracellular cytokine assay. Survival was compared to historical controls. Results: The vaccination schedule resulted in sustained intracellular IL-2 induction in PBLCs in 9 of 23 patients (39%) who received at least three doses. Cytokine induction became apparent within the first three administrations of vaccine and was maximal at 8-12 weeks. Induction of intracellular IL-2 production (group 1) was associated with improved survival (P < 0.036). The median survival of the nine patients demonstrating IL-2 induction was 59 (95% confidence interval (95% CI): 47-71) weeks compared to 31 (95% CI: 1844) weeks for the non- inducers. Induction of INF-γ (group 2) was found in 10 patients and 6 patients had IL-2 and INF-γ induction(group 3). There was no survival advantage for these patient groups. Although no objective responses were documented the group as a whole had a median survival of 44 (95c% CI: 31-59) weeks which is better than that of historical controls. SRL 172 was safe and well tolerated. Conclusion: SRL172 is effective in inducing intracellular IL- 2 responses in PBLCs of a significant number of patients with stage IV (AJCC) melanoma. This is correlated with improved survival. The survival analysis is sufficiently encouraging to suggest that further prospective trials are justified. The methodology we present in this study may help in developing surrogate markers that will allow rational immunotherapeutic strategies to be designed for cancer patients.

KW - Cancer vaccines

KW - Cytokines

KW - Melanoma

KW - Mycobacterium vaccae (SRL 172)

UR - http://www.scopus.com/inward/record.url?scp=0032812103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032812103&partnerID=8YFLogxK

U2 - 10.1023/A:1008307821189

DO - 10.1023/A:1008307821189

M3 - Article

C2 - 10470429

AN - SCOPUS:0032812103

VL - 10

SP - 817

EP - 824

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -